| Literature DB >> 23874465 |
Sue Jordan1, Alan Watkins, Mel Storey, Steven J Allen, Caroline J Brooks, Iveta Garaiova, Martin L Heaven, Ruth Jones, Sue F Plummer, Ian T Russell, Catherine A Thornton, Gareth Morgan.
Abstract
BACKGROUND: The vulnerability of clinical trials to volunteer bias is under-reported. Volunteer bias is systematic error due to differences between those who choose to participate in studies and those who do not. METHODS ANDEntities:
Mesh:
Year: 2013 PMID: 23874465 PMCID: PMC3706448 DOI: 10.1371/journal.pone.0067912
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Recruitment strategies considered.
| Strategy | Used | Advantages | Disadvantages | Findings |
| Non-targeted | ||||
| Written information distributed by a) midwives to all women attending booking clinics in primary care from 12 weeks’ gestation b) receptionists to all women attending hospital for routine 20 week ultrasound scan | Yes | Maximum coverage of population of pregnant women. (We estimate that >99% women in our area book for (free) antenatal care.) Not labour intensive. | Risks non-contact bias by failing to contact those not booking, typically the most disadvantaged. Assumes literacy. Information is not tailored to individuals’ needs, health beliefs or world views. Relies on health service staff. | Recruitment |
| Media: website, TV, local press and radio | Yes | Reaches a wide audience amongst the ‘less ill’, including partners and families | Advertising costs. Impact may be disappointing | We observed little impact. Following TV coverage, we received five telephone calls, all from women living outside the catchment area or already delivered. Two (0.5%) recruits first heard of the trial on TV and 7 (1.7%) via radio. We do not know whether the media had any more subtle effects in preparing families for researchers’ approaches. |
| Monetary incentives | No | The most effective strategy to improve recruitment. A ‘dose-response’ effect is suggested | Not recommended for research involving children in the UK [98∶90]. | We offered no inducements, and no-one mentioned ‘Getting things for free’ |
| Targeted | ||||
| Personal approach in hospital antenatal clinics. | Yes | A personal approach tailors presentation of the trial to each individual’s health beliefs, world views or need for information | Insufficient resources to speak with all women. Labour intensive and therefore costly. Risks non-contact bias by excluding those not attending, typically the most disadvantaged. | A personal approach improved the socio-demographic representation of the recruited sample by allowing researchers to tailor presentation of the trial to each individuals’ need for information |
| Personal approach in community groups (in this study, parenting and aquanatal classes). | Yes | In the USA, involvement in community groups, at church or civic events, increased recruitment of women from ethnic minorities | Some classes are poorly attended. Labour intensive, often outside office hours. | Only 20/454 (4.4%) women were recruited this way. Their deprivation scores were not significantly different from the whole sample. The effectiveness of this recruitment strategy is likely to be context specific. |
Figure 1Participant Flow Diagram for observation study to 6 month contact point.
Figure 2Participant Flow Diagram for observation study to 2 year contact point.
Comparisons between the recruited sample and external data.
| Source of comparison data | Trial data | Comparator data | Test | ||
| Mean [SD] | Mean [SD] | t test | significance, effect size | ||
|
| All-Wales health services’ electronic database, SAIL (n = 6,893) | 0.09 [4.21] | 0.79 [4.08] | 3.44, df 511 | p<0.001, r 0.15 |
|
| All-Wales health services’ electronic database, SAIL | 925.58 [624.10] | 1037.60 [591.3] | 3.74, df 495 | p<0.001, r 0.17 |
|
|
|
|
| ||
|
| All-Wales health services’ electronic database, SAIL | 136/454 (30%) | 1,327/6,893 (19.3%) | 29.9 | 1.79, 1.45–2.21 |
|
| 2001 Census, South West Wales | 149/454 (32.8%) | 43,474/98,136 (44.3%) | 24.14 | 0.61, 0.50–0.75 |
|
| Welsh Health Survey 2007 | 104/454 (23%) | 291/2,908 (10%) | 61.79 | 2.67, 2.08–3.43 |
|
| Welsh Health Survey 2007 | 83/441 (19%) | 203/2,541 (8%) | 49.61 | 2.67, 2.02–3.53 |
|
| 2001 Census, South West Wales | 15/398 (3.8%) | 8,304/503,256 (1.65%) | 9.72 | 2.33, 1.39–3.91 |
|
| Infant feeding survey, pregnant women in Wales 2005 | 73/454 (16%) | 457/2,076 (22%) | 7.57 | 0.68, 0.52–0.89 |
|
| Infant feeding survey, pregnant women in Wales 2005 | 193/453 (43%) | 1,141/2,085 (55%) | 21.44 | 0.61, 0.50–0.75 |
Notes to table: No correction taken for multiple comparisons.
Deprivation (Townsend) scores, ranks and fifths are based on geographical area of residence, using Lower Super Output Areas (LSOAs) defined by postcodes. This measure of material deprivation is calculated from rates of unemployment, vehicle ownership, home ownership, and overcrowding [49].
In five cases, both parents were students, and ONS categories could not be allocated. Fathers’ occupations taken where no occupation for mother [44], [49].
as reported by mothers at recruitment at 36 weeks’ pregnancy.
as in hospital records.
unequal sample sizes, unequal variances.
Figure 3Proportion in each deprivation (Townsend) fifth in the population and each stage of the trial.
Figure 4Proportion of participants from ONS Category 3 at each stage of the trial.
Figure 5Comparison of proportion of smokers at each stage of the trial.
Figure 6Women lost to follow up at 6 months compared with the whole sample.
Factors affecting trial participation at 6 months and 2 years: adjusted analyses.
| Clinic attendance 6 months | Consent to skin-prick testing 6 months | Retention in study 2 years | Attendance at clinic 2 years | Consent to skin-prick testing 2 years | Consent to blood sample donation 6 months | ||
| Numbers in analysis | 413 | 408 | 408 | 408 | 408 | 404 | |
| OR. (95% CI.) | OR. (95% CI.) | OR. (95% CI.) | OR. (95% CI.) | OR. (95% CI.) | OR. (95% CI.) | ||
|
| 1.08 (1.03–1.14) | 1.06 (1.01–1.11) | 1.09 (1.02–1.15) | 1.06 (1.02–1.10) | 1.05 (1.00–1.09) | NS | |
|
| 0.30 (0.15–0.62) | 0.32 (0.16–0.65) | 0.50 (0.23–1.09) | NS | NS | 0.43 (0.22–0.83) | |
|
| |||||||
| Most deprived fifth | 0.86 (0.73–0.99) | NS | NS | 0.86 (0.75–0.97) | NS | NS | |
|
| |||||||
| • ONS category 3 | NS | 0.75(0.57–0.99) | 0.68 (0.48–0.96) | NS | 0.79 (0.62–0.996) | 0.72 (0.57–0.92) | |
|
| 2.36 (1.26–4.41) | 1.93 (1.09–3.42) | 1.95 (0.92–4.11) | 1.97 (1.19–3.26) | 1.78 (1.12–2.82) | NS | |
|
| 1.93 (1.03–3.60) | 2.11 (1.16–3.86) | 2.27 (1.14–4.35) | 2.54 (1.62–4.00) | 1.96 (1.27–3.02) | NS | |
|
| |||||||
| Yes, very much or to some extent* | |||||||
| • Uncertain, don’t know | 0.37 (0.15–0.91) | 0.37 (0.17–0.86) | NS | 0.50 (0.27–0.95) | 0.55 (0.31–1.00) | 0.28 (0.14–0.54) | |
| • Not at all | 0.25 (0.12–0.53) | 0.34 (0.17–0.68) | NS | 0.55 (0.32–0.94) | 0.51 (0.31–0.85) | 0.49 (0.29–0.82) | |
|
| |||||||
| Yes, very much* | |||||||
| • Yes, to some extent | 0.46 (0.24–0.86) | 0.42 (0.23–0.77) | NS | NS | NS | NS | |
| • Uncertain, don’t know | 0.39 (0.15–1.00) | 0.35 (0.14–0.86) | NS | NS | NS | NS | |
| • Not at all | 0.23 (0.09–0.57) | 0.17 (0.07–0.41) | NS | NS | NS | NS | |
|
|
|
|
|
|
| ||
|
| |||||||
| Yes, very much * | |||||||
| • Yes, to some extent | NS | NS | NS | NS | NS | 0.50 (0.30–0.83) | |
| • Uncertain, don’t know | NS | NS | NS | NS | NS | 0.96 (0.47–2.06) | |
| • Not at all | NS | NS | NS | NS | NS | 0.29 (0.14–0.62) | |
|
| NS | NS | NS | NS | 2.83 (1.37–5.84) | ||
|
| NS | NS | NS | NS | NS | 0.46 (0.19–1.09) | |
|
| NS | NS | NS | NS | NS | 1.72 (0.97–3.03) | |
|
| NS | NS | NS | NS | NS | 1.74 (1.13–2.69) | |
| Hosmer and Lemeshow test (df 8) |
|
|
|
|
|
| |
| Nagelkerke R | 0.33 |
|
|
|
|
| |
| −2 log likelihood (LL) (df) | 337.24 (10) | 361.33 (10) | 250.41 (5) | 457.704 (6) | 496.332 (5) | 487.47 (11) | |
|
| |||||||
| Overall | 80.6 | 79.2 | 88.0 | 72.2 | 68.6 | 66.3 | |
| Participation | 93.6 | 93.0 | 99.2 | 91.2 | 85.8 | 75 | |
| Non-participation | 39.4 | 38.8 | 0 | 30.2 | 40.3 | 56.4 | |
Notes to table:
Variables entered are listed in Tables S1 and S2. Categories were collapsed to avoid low numbers, as necessary. A backwards likelihood ratio criterion was used to select predictor variables. Reports of asthma and eczema were tested separately and together. Models were checked by two of us and found to be robust: removal of outliers made no overall difference. Not all participants responded to all questions. Missing data in some variables reduced the number cases in the analyses. We did not impute values.
Most adverse events related to symptoms typical of common problems in routine clinical practice. None were attributed to the trial intervention by the trial’s data monitoring committee [35].
Not all rashes had been diagnosed by a professional: carer’s report was the variable of interest.
Testing was not offered to 5 infants, who were excluded from this analysis. NS represents ‘not significant’. * denotes reference category.
Changes in regression models with addition of predictor variables.
| 6 month clinic attendance | 2 year clinic attendance | Blood sample donation | |||||||||||||||
| Predictors added | Overall prediction (%) | Attenders predicted (%) | Non-attenders predicted (%) | Nagelkerke R2 | −2 log likelihood (−2LL) (df) | Overall prediction (%) | Attenders predicted (%) | Non-attenders predicted (%) | Nagelkerke R2 | −2 log likelihood (−2LL) (df) | Overall prediction (%) | Consent predicted (%) | Declining predicted (%) | Nagelkerke R2 | −2 log likelihood (−2LL) (df) | ||
| i) Socio-demographic and health-related: ONS category, deprivation fifths, maternal age, smoking status, asthma or eczema in parents | 75.7 | 91.1 | 38.5 | 0.20 | 469.30 (3) | 67.9 | 86.5 | 32.4 | 0.11 | 541.67 (3) | 62.9 | 72.5 | 53.7 | 0.11 | 576.89 (6) | ||
| ii) Leverage: reports of rash or adverse event in infant | 78.2 | 93.7 | 32.7 | 0.22 | 408.74 (5) | 70.9 | 89.7 | 34.2 | 0.17 | 506.96 (4) | No change | ||||||
| iii) Reasons for joining the trial | 80.6 | 92.9 | 40.4 | 0.33 | 337.24 (10) | 72.2 | 91.2 | 30.2 | 0.18 | 457.70 (6) | 66.3 | 75.0 | 56.4 | 0.21 | 487.47 (11) | ||
|
| |||||||||||||||||
| Addition of rashes and adverse events (leverage factors) | ?2 60.56, df = 2, p<0.001 | ?2 34.67, df = 1, p<0.001 | NS | ||||||||||||||
| Addition of reasons for joining the trial | ?2 71.51, df = 5, p<0.001 | ?2 51.22, df = 2, p<0.001 | ?2 89.42, df = 5, p<0.001 | ||||||||||||||
Note to table:
To obtain a measure of the impact of factors relating to the three categories listed, we calculated the reductions in −2LL at each stage.
Clinical outcomes by 2 years according to trial arm: weighted, unweighted and subgroup analyses.
| Unweighted analysis: Whole sample | Weighted analysis: Whole sample | Unweighted analysis: Least deprived fifth. | Unweighted analysis: Deprivation fifths 2–4 only | Unweighted analysis: Most deprived fifth | |||||||||||||
| Variable | Probiotic arm N = 220 n(%) | Placebo arm N = 234 n(%) | OR (95% CI) | ARR% (95% CI) | Probiotic arm n(%) | Placebo arm n(%) | OR (95% CI) | ARR% (95% CI) | Probiotic arm N = 66 n(%) | Placebo arm N = 70 n(%) | OR (95% CI) | Probiotic arm N = 99 n(%) | Placebo arm N = 96 n(%) | OR (95% CI) | Probiotic arm N = 55 n(%) | Placebo arm N = 68 n(%) | OR (95% CI) |
|
| |||||||||||||||||
| Positive to ≥1 allergen at either 6 months or 2 years | 18/171 (10·5) | 32/173 (18·5) | 0·52 (0·28–0·98) | 8.0* (0.5–15.4) | 18/169 (10.7) | 32/172 (18.6) | 0.52 (0.28–0.97) | 8.0* (0.5–15.4) | 7/58 (12.1) | 12/64 (18·8) | 0·60 (0·22–1·63) | 9/77 (11.7) | 10/71 (14·1) | 0·81 (0·31–2·12) | 2/36 (5.6) | 10/38 (26·3) | 0·17 (0·03–0·82) |
|
| |||||||||||||||||
| Atopic eczema | 9/171 (5·3) | 21/173 (12·1) | 0·40 (0·18–0·91) | 6.9* (0.9–13.1) | 11/170 (6.50) | 19/172 (11.0) | 0.56 (0.26–1.21) | 4.6* (–1.4–10.5) | 2/58 (3·4) | 11/64 (17·2) | 0·17 (0·04–0·81) | 5/77 (6.5) | 5/71 (7·0) | 0·91 (0·25–3·31) | 2/36 (5.6) | 5/38 (13.2) | 0·39 (0·07–2·14) |
| Eczema diagnosed by a doctor | 73/214 (34·1%) | 72/222 (32·4%) | 1·07 (0·72–1·60) | 1.7† (–7.1–10.5) | 75/205 (36.6) | 71/219 (32.4) | 1.20 (0.81–1.80) | 4.2† (–4.9–13.2) | 21/66 (31·8%) | 28/68 (41·2%) | 0·67 (0·33–1·35) | 34/97 (35·1%) | 26/90 (28·9%) | 1·33 (0·72–2·46) | 18/51 (35.3) | 18/64 (28·1) | 1·40 (0·63–3·08) |
|
| |||||||||||||||||
| Asthma diagnosed by a doctor | 22/193 (11.4) | 20/199 (10.1) | 1.15 (0.61–2.19) | 0.2† (–6.2–6.7) | 24/189 (12.7) | 21/200 (10.5) | 1.24 (0.67–2.31) | 1.1† (–5.1–7.4) | 5/64 (7.8) | 5/65 (7.7) | 1.02 (0.28–3.70) | 10/87 (11.5) | 8/79 (10.1) | 1.50 (0.43–3.09) | 7/42 (16.7) | 7/55 (12·7) | 1·37 (0·44–4·27) |
Notes to table:
ARR (absolute risk reduction), calculated only for whole sample. * favours probiotics † favours placebo.
Weighted numbers differ from original numbers. Cell counts were rounded by spss.
All sample, intention to treat.